News

   

Asarina Pharma presents first-in-class PMDD treatment to investors in Gothenburg and Stockholm

On August 28 Asarina Pharma applied to be listed on Nasdaq First North, generating significant interest. On Tuesday, September 4 the company presents to investors at Aktiekvällen in Gothenburg, followed by further events in Stockholm.

Full PDF
   

Asarina Pharma AB offentliggör prospekt i samband med nyemission om 142,8 MSEK inför notering på Nasdaq First North

Styrelsen i Asarina Pharma AB (”Asarina Pharma” eller ”Bolaget”) har beslutat att genomföra en nyemission om högst 6 800 000 aktier samt notera Bolagets aktier på Nasdaq First North. Teckningskursen uppgår till 21 SEK per aktie, vilket motsvarar ett emissionsbelopp om högst 142,8 MSEK (”Erbjudandet”). Baserat på emissionskursen och befintligt antal aktier värderas Bolaget till omkring 172…

Full PDF
   

Asarina Pharma AB publishes prospectus in connection with share issue of SEK 142,8M and listing on Nasdaq First North

The Board of Asarina Pharma AB (“Asarina Pharma” or the “Company”) has resolved on a share issue of up to 6,800,000 shares and has decided to apply for admission to trading of the Company’s share on Nasdaq First North. The subscription price amounts to SEK 21 per share, which corresponds to an issue amount of…

Full PDF
   

Chief Medical Officer appointed for clinical trials of world’s first therapy targeting both PMDD and menstrual migraine

Stockholm – June 29, 2018. A small Swedish pharmaceutical company has taken another step towards being the first company in the world to launch a targeted treatment for PMDD—the most debilitating form of PMS. Dr Märta Segerdahl has been appointed Chief Medical Officer, with over 20 years’ experience in pain medicine, including menstrual migraine.

Full PDF
   

Asarina Pharma: New cross-border Board reflects global potential of therapy

Stockholm – May 31, 2018. Asarina Pharma’s new Board reflects the global potential of its first-in-class therapy for PMDD. New members include senior pharma, science and research professionals from a range of countries contributing a powerful mix of skills.

Full PDF